Deepa Rangachari - Concepedia

Author

Deepa Rangachari

Beth Israel Deaconess Medical Center ORCID

Also Known As

D. Rangachari, Deepa Rangachari, Patell, Rushad

146

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Beth Israel Deaconess Medical Center Harvard University Dana-Farber Cancer Institute Massachusetts General Hospital Johns Hopkins University

About

Deepa Rangachari is an author at Beth Israel Deaconess Medical Center specializing in lung cancer, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1K
2	Health Sciences	4	4	128
3	Cell Biology	2	2	263
4	Education	1	1	22
5	Nursing	1	1	22

Deepa Rangachari

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers Deepa Rangachari, Norihiro Yamaguchi, Paul A. VanderLaan, Lung Cancer	2015	509
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer Anna F. Farago, Beow Y. Yeap, Marcello Stanzione, Cancer Discovery	2019	231
Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes Paul A. VanderLaan, Deepa Rangachari, Susan M. Mockus, Lung Cancer Lung CancersOncologyMedicinePathologyCancer Genomics	2017	207
Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma Deepa Rangachari, Paul A. VanderLaan, Meghan Shea, Journal of Thoracic Oncology Tumor BiologyOncologyMedicineLung AdenocarcinomaCancer Cell Biology	2017	126
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer Lorena Ostios-García, Jennifer Faig, Giulia C. Leonardi, Journal of Thoracic Oncology OncologyImmunologyPd-1 InhibitorsAntiviral Drug DevelopmentAntiviral Therapy	2018	91
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples Deepa Rangachari, Ciric To, Jason Shpilsky, Journal of Thoracic Oncology	2019	89
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors Pedro Eduardo Nascimento Silva Vasconcelos, Carol Gergis, Hollis Viray, JTO Clinical and Research Reports	2020	79
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation Susan E. Jorge, Sol Schulman, Jason A. Freed, Lung Cancer Met AmplificationOncogenic AgentMedicinePathologyCancer Genomics	2015	78
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? Vanda F. Torous, Deepa Rangachari, Benjamin P. Gallant, Journal of the American Society of Cytopathology Cancer ImmunosurveillanceClone 22C3Cell Lung CancerMedicineImmunology	2018	63
Tumor biomarker testing in non-small-cell lung cancer: A decade of change Paul A. VanderLaan, Deepa Rangachari, Adnan Majid, Lung Cancer Prognostic BiomarkersNon-small-cell Lung CancerCancer DetectionMedicineBiomarker Target	2018	61

Page 1